Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings
About Harbin Pharmaceutical Group Co.,Ltd.
Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 哈药集团股份有限公司关于控股股东部分股份解除质押及质押的公告 | 2025-10-14 | Chinese | |
| 哈药集团股份有限公司关于控股股东部分股份质押延期购回的公告 | 2025-10-10 | Chinese | |
| 哈药集团股份有限公司2025年第一次临时股东大会会议材料 | 2025-09-29 | Chinese | |
| 哈药集团股份有限公司董事会薪酬与考核委员会工作细则（2025年9月修订） | 2025-09-26 | Chinese | |
| 哈药集团股份有限公司规范与关联方资金往来的管理制度（2025年9月修订） | 2025-09-26 | Chinese | |
| 哈药集团股份有限公司董事离职管理制度（2025年9月） | 2025-09-26 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 41339930 | 哈药集团股份有限公司关于控股股东部分股份解除质押及质押的公告 | 2025-10-14 | Chinese | ||
| 41339922 | 哈药集团股份有限公司关于控股股东部分股份质押延期购回的公告 | 2025-10-10 | Chinese | ||
| 41339910 | 哈药集团股份有限公司2025年第一次临时股东大会会议材料 | 2025-09-29 | Chinese | ||
| 41339898 | 哈药集团股份有限公司董事会薪酬与考核委员会工作细则（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339895 | 哈药集团股份有限公司规范与关联方资金往来的管理制度（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339884 | 哈药集团股份有限公司董事离职管理制度（2025年9月） | 2025-09-26 | Chinese | ||
| 41339875 | 哈药集团股份有限公司董事会秘书工作制度（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339865 | 哈药集团股份有限公司董事会议事规则（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339851 | 哈药集团股份有限公司股东会议事规则（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339843 | 哈药集团股份有限公司章程（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339825 | 哈药集团股份有限公司董事、监事、高级管理人员所持本公司股份及其变动管理制度（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339814 | 哈药集团股份有限公司董事会战略决策委员会工作细则（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339807 | 哈药集团股份有限公司董事会提名委员会工作细则（2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339795 | 哈药集团股份有限公司董事会审计委员会工作细则(2025年9月修订） | 2025-09-26 | Chinese | ||
| 41339785 | 哈药集团股份有限公司市值管理制度（2025年9月） | 2025-09-26 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Harbin Pharmaceutical Group Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56904/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56904 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56904 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56904 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56904}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Harbin Pharmaceutical Group Co.,Ltd. (id: 56904)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.